Business Wire

REPLY

8.7.2020 09:02:09 CEST | Business Wire | Press release

Share
Reply Creative Challenge 2020: Team Trecento11 Wins Europe's Greatest Creative Challenge for Students and Young Creatives from all over the World

With the project “Proud to share” Team Trecento11 secured the victory of the 2020 edition of the Creative Challenge , the largest competition in Europe for students and young creatives organized by Reply and part of the online team-based series of competitions, Reply Challenges.

Launched last May 22nd with the online qualification marathon (running 48h), the challenge gathered over 6,200 creative talents (+77% vs. 2019 edition) from more than 70 countries around the World to focus their creative efforts on five categories: Employer Branding, Brand Activation, Service Design, Branded Content and Social Media:Instagram .

Spread across over 1,000 teams, the young talents - with an average age between 18 and 29 - put their skills and personalities into the development of a creative concept based on a brief assigned by some of the most renowned marketing and communication professionals in Europe.

This year's challenge was characterized by the need to rethink consumer engagement strategies to respond to the spread of the pandemic. During the development of the projects explicit references to the events of the past few months were made, with numerous proposals focused on the restart.

Of the 500+ proposals submitted it was the projects “Proud to share ” (for Martini) , “Work for Zero ” (for MSC), “Remember your Nature ” (for FCA), “Scrambler Ducati Experience Fest ” (for Ducati Scrambler) and “Meetisto ” for (OBI), that were praised most highly for their level of innovation and overall quality. As a result the teams Brian, Glamour, S57, Trecento11 and Lavor progressed to the final round, during which they had the opportunity to exhibit their concepts to an exceptional jury composed of the Art and Creative Directors of Reply agencies (Avvio Reply, Bitmama, Open Reply, Triplesense Reply, Xister Reply) and the Brand Partners of the initiative: Ducati Scrambler, FCA, Martini, MSC Cruises and OBI.

Live streamed on Facebook and YouTube, the presentations were judged on a combination of elements and skills including the adherence to the briefs assigned and the highly original materials produced. Team Trecento11 finished top of the podium, presenting an idea for Brand Activation focused on concepts of sharing experiences and enhancing interpersonal relationships in a time when the aperitif is increasingly "digital" compared to the past and the typical physicality of the moment.

Team Trecento11 brought together 91 years of creative experience and 311 kilometres of distance between its four members: Gianluca Sebastiani (23 years old), Ivan Morra (23 years old), Michael Grego (22 years old) and Michele Gionta (23 years old). Hence the "creative" origin of the team's naming, with the team commenting: "Working during the lockdown imposed a lot of limits on us. With 311 km between us we had to work on video calls and it wasn't easy to manage everything remotely, from brainstorming to crafting, to thinking about feasible activation during a pandemic. However, limits often stimulate creativity and that's what happened with #ProudToShare".

The Creative Challenge is part of the Reply Challenges 2020 competition series organized by Reply for young students, talents and technology enthusiasts to promote the culture of coding and stimulate digital innovation in the fields of creativity, cybersecurity and finance.

To find out more about the Creative Challenge 2020 please visit challenges.reply.com .

Reply
Reply [MTA, STAR: REY] specializes in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye